Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Study acronym: SABLe
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Aug 1, 2025 to Dec 1, 2025
    • Eligibility criteria expanded, about 32 words
    • Site details revised at 1 of 11 sites
  2. Primary completion date: Jun 1, 2024 to Aug 1, 2025v6
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 11 of 11 sites
    v5
  4. Enrollment target: 100 to 50
    • Study description shortened, about 22 words
    • Study sites revised (11)
    • Study arms: 2 to 1
    v4
  5. Study sites: 7 to 11v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Apr 1, 2021 to Aug 18, 2021
    • Site details revised at 7 of 7 sites
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group
Trial Details
NCT Number NCT04717700
Lead Sponsor Ida Bruun Kristensen
Collaborators: Karyopharm Therapeutics Inc, Odense Patient Data Explorative Network
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov